- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Nycomed releases Diatide milestone payment
Radiopharmaceutical firm Diatide reported last month that it received an expected $2 million milestone payment from marketing partner Nycomed Amersham. The payment is in response to Diatide's filing of new drug application (NDA) for NeoTect, a lung
Radiopharmaceutical firm Diatide reported last month that it received an expected $2 million milestone payment from marketing partner Nycomed Amersham. The payment is in response to Diatide's filing of new drug application (NDA) for NeoTect, a lung cancer imaging agent formerly called P829.
Nycomed's payment comes only weeks after the Buckinghamshire, U.K., firm announced that it would terminate an option and development agreement with Diatide for some products (SCAN 8/19/98). At the time of the announcement, both firms emphasized that Nycomed's withdrawal would not affect its marketing of NeoTect or AcuTect, Diatide's technetium-labeled agent for the detection and localization of acute venous thrombosis. The FDA could clear AcuTect this month, according to Diatide executives.
The Londonderry, NH, firm submitted its NeoTect NDA in June and has received a six-month priority classification from the Food and Drug Administration. The company expects NeoTect to be approved by the end of the year. Nycomed will pay Diatide another $2 million when the agent is approved.
Can AI Enhance PET/MRI Assessment for Extraprostatic Tumor Extension in Patients with PCa?
December 17th 2024The use of an adjunctive machine learning model led to 17 and 21 percent improvements in the AUC and sensitivity rate, respectively, for PET/MRI in diagnosing extraprostatic tumor extension in patients with primary prostate cancer.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
